1. Home
  2. LDOS vs RPRX Comparison

LDOS vs RPRX Comparison

Compare LDOS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leidos Holdings Inc.

LDOS

Leidos Holdings Inc.

HOLD

Current Price

$158.54

Market Cap

22.5B

Sector

Technology

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$48.37

Market Cap

19.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDOS
RPRX
Founded
1969
1996
Country
United States
United States
Employees
47000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
19.5B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
LDOS
RPRX
Price
$158.54
$48.37
Analyst Decision
Buy
Strong Buy
Analyst Count
13
4
Target Price
$207.77
$50.00
AVG Volume (30 Days)
789.4K
2.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.10%
1.93%
EPS Growth
20.82
N/A
EPS
11.14
1.78
Revenue
$17,174,000,000.00
$2,378,193,000.00
Revenue This Year
$5.59
$38.30
Revenue Next Year
$4.06
$4.80
P/E Ratio
$14.03
$27.41
Revenue Growth
3.07
5.06
52 Week Low
$136.91
$31.58
52 Week High
$205.77
$49.06

Technical Indicators

Market Signals
Indicator
LDOS
RPRX
Relative Strength Index (RSI) 44.08 61.00
Support Level $154.52 $35.32
Resistance Level $164.44 $49.06
Average True Range (ATR) 3.68 0.90
MACD 0.67 0.06
Stochastic Oscillator 68.69 81.00

Price Performance

Historical Comparison
LDOS
RPRX

About LDOS Leidos Holdings Inc.

Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: